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A novel membrane-bound serine esterase in cultueed human T4’ lymphocytes, recently purified and named tryptase TL,, binds specifically to the 
external envelope protein gp120 of HIV-I, interacting with its V3 domain. This binding was selectively blocked by inhibitors of tryptase TL, with 
a GPCR sequence in their reactive site, synthetic peptides corresponding with the sequences of the V3 domains of various HIV-I strains with the 
GPGR sequence, and antibody against tryptase TL,, or neutralizing antibody against the V3 domain of HTLV-111~. These findings suggest that 
tryptase TL, is a binding protein of the V3 domain of HIV-1 envelope glycoprotein. 
AIDS; HIV-l gpl20; V3 domain; Serine esterase; Binding protein 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Human immunodeficiency virus (HIV-l) utilizes the 
CD4 antigen as a receptor for binding to the cell surface 
[l-3]. Although little is understood about the sequence 
of events occurring between CD4 binding and viral in- 
ternalization, several observations uggest hat some 
factor(s) involved in the events following binding to 
CD4 effects membrane fusion and internalization 
(la-81 * 
2.1. Materials 
The compounds used were as follows: porcine pancreatic trypsin, 
leupeptin and aprotinin (Sigma), gpl20 of HTLV-Illa 
(MicroGenesys), mouse monoclonal antibody (mmab)-anti-HIV-1 
gpl20 and neutralizing mmab-anti-HIV-1 gpl2ON (DuPont), mmab- 
anti-Leu 3a (Becton Dickinson), and “‘1 as sodium salts 
(3.7 CBq/ml) (Amersham). Tryptase TL2 and trypstatin were 
purified as described [9,11]. HI30 and recombinant At-g-IS, Glu-St 
aprotinin were gifts from Dr H. Fritz, University of Munich. 
We have demonstrated that trypstatin [9] and anti-rat 
mast cell tryptase antibodies markedly inhibited 
multinucleated cell-to-cell fusion (syncytia) induced by 
HIV-1 [lo]. We recently purified a novel membrane- 
bound serine esterase, named tryptase TL2, from 
human T4+ lymphocytes immunologically reactive with 
the antibody inhibiting syncytial formation [l 11. The 
amidase activity of tryptase TL2 was strongly inhibited 
by gp120 of human T-lymphotropic virus (HTLV) type 
I&, by synthetic peptides with a central Gly-Pro-Gly- 
Arg (GPGR) motif, corresponding to the V3 domains 
of gpl2Os of various kIV-1 strains, and by Kunitz-type 
inhibitors, such as trypstatin and HI30 [ 121, containing 
the sequence GPCR in their reactive site [ll]. These 
results suggest hat gp120 of HIV-l binds to tryptase 
TL2 at a site other than the CD4 receptor. In this report, 
we demonstrated that gp120 of HIV-l specifically binds 
to tryptase TLz in the region of the V3 domain. 
2.2. *Assay of gpl20 binding to tryptuse TLz 
HTLV-IlIa gpl20 and purified tryptase TLz were radioiodinated by 
the method of Bolton and Hunter [ 131, Radioiodinated gpl20 (0.4 kg) 
was incubated with 0.4cg of tryptase TLz in 40 pl of 100 mM Tris- 
HCI, pH 8.5, at 37°C for 30 min. The reaction was stopped by addi- 
tion of 1 mM leupeptin and then 4Opl of 50% polyclonal antibody 
against tryptase TLz coupled with Sepharose 4B was added. After in- 
cubation at room temperature for 1 h with vigorous shaking, the 
Sepharosc 413 was washed three times with 1 ml of 10 mM Tris-HCI, 
pH 7.0, containing 0,s M NaCl and 0,05% Tween 20, and once with 
1 ml of 10 mM Tris-HCI, pH 7.0 and its radioactivity was counted. 
Conversely, [‘*‘l]tryptase TLz was incubated with gpl20 and im- 
munoprecipitated with mmab-gpl20-coupled Sepharosc 48. Non- 
specific binding was determined by incubation of [‘2’1]gp120 or 
[ “l]tryptase TLz with 40~1 of 50% uncoupled Sepharose 4B. Bound 
proteins were eluted with 20 cl of sample loading buffer at 100DC for 
5 min and analyzed by IO-20% polyacrylamide gradient gel elec- 
trophoresis (PAGE) under reducing conditions in sodium dodecyl 
sulphate (SDS) (14) followed by autoradiography. 
ADDreviurions: HIV, human imtnuuodeficicncy virus: HTLV, human 
I’-lymphorropic virus; mmab, mouse monoclonal antibody; PAGE, 
polyacrylamide gel electrophoresis; SDS, sodium dodecyl sulfotc 
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The effects of inhibitors, peptides and antibodies other than anti- 
tryptasc TLz on the binding of gpl20 to tryptase TL, were tested by 
incubation of [‘2”IJgp120 (0.4pg) with purified tryptasc TLr (0.4 /lg) 
in the presence or absence of inhibitors, peptidcs and antibodies and 
then with 40 ~1 of SO% anti-tryptase TL2 IgG coupled with Sepharose 
4B. The effect of anti-tryptase TL2 was tested by incubation of 
[““l]tryptase TL.2 (0.4~~) with gpl20 (0.4pg) in the presence or 
absence of rhc antibody and then whh mmab-gpl20 coupled with 
Sepharosc 4i3, The Scpbnrose 4i3 was then precipitated and washed 
and its radioac(ivity was counted. 
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3. RESULTS AND DISCUSSION 
3.1. Specific binding of gp120 to tryptase TL2 
To determine whether HTLV-111~ gp120 binds to 
tryptase TL2, we incubated [‘251]gp120 with purified 
tryptase TLt and then treated the mixture with anti- 
tryptase TL2 IgG-Sepharose 4B. As shown in Fig. IA, 
lane 2, [‘251]gp120 was co-immunoprecipitated with 
tryptase TL2. [‘251]gp120 was not immunoprecipitated 
by the antibody in the absence of tryptase TL2 (lane 6) 
and gave only a very faint band with non-immunized 
IgG-Sepharose 4B (lane 5). [‘251]gp120, used as a 
positive control, was almost completely im- 
munoprecipitated by mmab-gp120 of MTLV-111s (lane 
1). No [tt51]gp120 was immunoprecipitated from mix- 
tures with trypsin (lane 3) or tryptase TLr, which is 
another arginine-cleaving protease purified from the 
cytosol fraction of human T4+ lymphocyte clone 
Molt-4, clone-8 cells (II. Kido et al., in preparation) 
(lane 4), and these proteases hydrolyzed the gp120 to 
fragments of various sizes (data not shown). Fig. 1B 
shows that immunoprecipitation of [‘2’I]gp120 in- 
creased with an increase in the concentration of tryptase 
TL2 in the assay mixture. Conversely [“‘Iltryptase TL2 
was co-immunoprecipitated by mmab-gp120 after in- 
cubation with gp120 (Fig. lC, lane l), but not without 
~3~120 (Fig. IC, lane 2). These results indicate that 
gp120 of HTLV-111~ recognizes and binds specifically 
to tryptase TL2. 
3.2. lnhibiriort of binding of gp120 fo tryptase TL.2 
The effects of inhibitors of tryptase TL2, synthetic 
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Fig. I. Specific binding of WTLV-111~1 gp 20 to tryptase TL2. (A) (Lane 1) [‘251]gp120 (0.4 pg) incubated without tryptase TLa following incubation 
with mmab-gp120 IgG-Sepharose 48; (lane 2) [‘2’1Jgp120 incubated with 0.4 /rg of tryptase TL2, then with anti-tryptase TL2 IgGSepharose 4B; 
(lane 3) [‘L51]gp120 incubated with 0.4 yg of trypsin, then with anti-trypsin IgG-Sepharose 4B; (lane4) [‘2SI]gp120incubated with 0.4 /cg of tryptase 
TLI, then with anti-tryptase TLI IgG-Sepharose 4B; (lane 5) [‘251]gp120 incubated with 0.4,~g of tryptase TLr, then with non-immunized rabbit 
IgG-Sepharose4B; (lane 6) [‘zsI]gp120 incubated without ryptase TLr, then with anti-tryptase TL2 IgG-Sepharose 4E. Bound proteins were eked, 
analyzed by SDS-PAGE and autoradiographed asdescribed in section 2. (B) [‘251]gp120 (0.4 pg) incubated without tryptase TLa (lane l), or with 
0.05 .ug (lane Z), 0.1 fig (lane 3), 0.2 gg (lane 4), 0.3 ,~g (lane 5), 0.4 ,ug (lane 6) or 0.6 fig (lane 7) of tryptase TLr, then with anti-tryptase TLz IgG- 
Sepharose 4B. (C) [‘2SI]Tryptase TL2 (0.4,ug) incubated with (lane 1) or without (lane 2) 0.4pg of gp120 and then with 40~1 of mmab-gpl20 lgG- 
Sepharose 4B. 
peptides and antibody against ryptase TL2 or neutraliz- 
ing antibody against he V3 domain of gp120 on the 
binding of HTLV-111~ gp120 to purified tryptase TL2 
are shown in Table I. Potential Kunitz-type protease in- 
hibitors of tryptase TL2, such as trypstatin [9] and HI30 
1121 with the sequence GPCR in their reactive site and 
Arg-15, Glu-52 aprotinin, in which Lys-15 in the reac- 
tive site is replaced by Arg-15, inhibited the binding. 
However, aprotinin, which has lysine in the reactive 
site, did not inhibit the binding, Leupeptin, which does 
not contain the GPCR sequence, also did not inhibit the 
binding, although it inhibited the amidase activity of 
tryptase TL2 [ll]. Synthetic peptides that correspond to 
the V3 domains of various HIV-1 strains and can inhibit 
the activity of tryptase TL2 [ll], such as NNT23 of 
HTLV-111~5, NNT24 of HTLV-111~ and YNK23 of 
HTLV-IIIMN, also inhibited the binding. 
To identify the amino acid sequences necessary for 
the inhibition, we tested the effects on the binding of 
several short peptides related to the NNT24 sequence, 
The peptides VT107 and AFV07 without the GPGR se- 
quence were not inhibitory, whereas the peptides 
GPG07, IQRlO, and IRI12 with the GPGR sequence 
were inhibitory, though less inhibitory than NNT24. As 
a negative control, peptide ASD15, corresponding to 
Ala-61 to Trp-75 of gp120 of HTLV-Illa, which was ar- 
bitrarily chosen as a sequence in a different position 
from those for CD4 binding and the V3 domain, had no 
inhibitory effect, These results suggest hat a central 
GPGR motif in the peptides is essential, but not enough 
on its own, for the inhibition. Anti-tryptase TL2 and 
neutralizing antibody against he V3 domain of HTLV- 
234 
I& gp120 (anti-gp12ON) also markedly blocked the 
binding, whereas non-immunized IgG and anti-CD4 an- 
tibody had no effect. These results support the conclu- 
sion that tryptase TL2 interacts with gp120 in the region 
of the V3 domain. 
Fig. 2. Absence of cleavage of yp120 after binding to tryptase TLz. 
gp 120 (I .S fig) was incubated with 0.05 ,ug of tryptasc TL2 in 20 id! of 
100 mM Tris-HCI buffer, pH 8.5, at 3’7OC for 0 mire (ianc I), 30 tnin 
(lane 2), 60 min (lane 3), 90 min (lane 4) or 180 min (lane 5) and then 
after reduction was analyzed by lo-20% SDS-PAGE, The gal was 
stained with Coomassie brilliant blue R-250, and destained. 
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Table I 
Inhibition of binding of HTLV-Illa gpl20 to tryptase TL2 
Addition Cons. Number” Sequence !nhibitionb 
(/IM) (%o) 
None 100 0 
Leupeptin 100 2.3 f 2.0 
Trypstatin 40 (1) AFAELPLAFDA 88.8 f 16.2 
HI30 40 (79) VAACNLPVIR AFIQLWAFDA 88.3 t 16.4 
Arg-15, Glu-52 aprotinin 100 (1) RPDFCLEPPYT ARIIRYFYNA 30.7 + 5.6 
Aprotinin 100 (1) RPDFCLEPPYT ARlIRYFYNA 2.2 it 2.6 
NNT23 (HTLV-111~~~) 400 (307) NNTKKGIAI TLYAREKUG 12.6 t 18.2 
YNK23 (HTLV-111~~) 400 (307) 46.3 + 13.6 
NNT24 (HTLV-IIIB) 400 (307) 84.2 f 20.1 
VT107 (HTLV-111~) 400 (324) VTIGKIG 0 ZlZ 2.0 
AFV07 (HTLV-111~) 400 (322) AFVTIGK 0 r 1.6 
GPGOS (HTLV-!!!a) 400 (318) GPGR AFVT 
!QR!O (HTLV-Illa) 400 (315) IQR GPGR AFV 
lRll2 (HTLV-111~) 400 (313) 0 
5.5 + 2.1 
15.7 & 2.6 
!RlQR GPGR AFV 15.9 it 2.3 
ASDI5 (HTLV-Illa) 400 (61) ASDAKAYDTEV HNVW 0 + 1.8 
Anti-gp12ON mmab 5 fig/m! (314) RIQR -1 AFVTIGK’ 94.1 Z?Z 12.1 
Anti-tryptase TLz IgG 50 a&/m! 83.2 rt 8.9 
Anti-CD4 mmab I .25 &ml 2.3 f 1.8 
Non-immunized !gG 50 fig/ml 4.8 f 2.8 
a Positions of amino acid residues are indicated. The sequences of the various strains of HIV-! listed are aligned at the cysteine residue 
at amino acid 302 according to the numbering system of Ratner et a!. [IS]. The listed sequences have all been published [9,!2,!5,16] 
’ Percentage inhibition was calculated as (count with inhibitor, peptide or antibody 2 count of non-specific binding)/(count without 
inhibitor, peptide or antibody - count of non-specific binding) x 100. Values are means f SD for 5 separate xperiments 
’ Amino acid sequence of the antigen peptide of mmab anti-gpl20N (DuPont) 
3.3. No cleavage of gp120 after binding to tryptase 
TL2 
For determination of whether gp120 bound to tryp- 
tase TL2 was cleaved proteolytically after binding, 
gp120 was incubated with tryptase TL2 and then analyz- 
ed by SDS-PAGE. As shown in Fig. 2, tryptase TLz did 
not’cleave gp120 during incubation for up to 180 min at 
37°C. This result indicates that the selective binding of 
the V3 domain of HIV-l gp120 to tryptase TL2 may be 
one step in infection. A requirement for the binding of 
the V3 domain to cell surface tryptase TL2 with a 
limited tissue .distribution may also be an important 
mechanism for restricting the host cell tropism of 
HIV-l. 
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